Eto M - Search Results

1

Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells.

Motoshima T, Komohara Y, Horlad H, Takeuchi A, Maeda Y, Tanoue K, Kawano Y, Harada M, Takeya M, Eto M. Motoshima T, et al. Among authors: eto m. Oncol Rep. 2015 Jun;33(6):2947-53. doi: 10.3892/or.2015.3893. Epub 2015 Apr 2. Oncol Rep. 2015. PMID: 25845968

2

Antitumor activity of interleukin-12 against murine bladder cancer.

Eto M, Harada M, Tamada K, Tokuda N, Koikawa Y, Nakamura M, Nomoto K, Naito S. Eto M, et al. J Urol. 2000 May;163(5):1549-52. J Urol. 2000. PMID: 10751886

3

Anti-tumour activity of heat-shock protein 60-recognizing CD4+ T cells against syngeneic murine renal cell carcinoma.

Eto M, Harada M, Tatsugami K, Harano M, Koga H, Matsuzaki G, Naito S. Eto M, et al. BJU Int. 2005 Feb;95(3):421-4. doi: 10.1111/j.1464-410X.2005.05313.x. BJU Int. 2005. PMID: 15679807

4

In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.

Ichikura H, Eto M, Ueno H, Harada M, Takayama K, Tokuda N, Tatsugami K, Naito S. Ichikura H, et al. Among authors: eto m. Oncol Rep. 2006 May;15(5):1333-7. Oncol Rep. 2006. PMID: 16596207

5

Molecular targeting therapy for renal cell carcinoma.

Eto M, Naito S. Eto M, et al. Int J Clin Oncol. 2006 Jun;11(3):209-13. doi: 10.1007/s10147-006-0577-2. Int J Clin Oncol. 2006. PMID: 16850127 Review.

6

Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease.

Eto M, Harano M, Tatsugami K, Harada M, Kamiryo Y, Kiyoshima K, Hamaguchi M, Tsuneyoshi M, Yoshikai Y, Naito S. Eto M, et al. Clin Cancer Res. 2007 Feb 1;13(3):1029-35. doi: 10.1158/1078-0432.CCR-06-1578. Clin Cancer Res. 2007. PMID: 17289899

7

Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor.

Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Harada M, Kiyoshima K, Hamaguchi M, Teshima T, Tsuneyoshi M, Yoshikai Y, Naito S. Eto M, et al. Clin Cancer Res. 2008 May 1;14(9):2833-40. doi: 10.1158/1078-0432.CCR-07-1742. Clin Cancer Res. 2008. PMID: 18451251

8

Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantation.

Hamaguchi M, Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Teshima T, Harada M, Yoshikai Y, Naito S. Hamaguchi M, et al. Among authors: eto m. Cancer Sci. 2009 Jan;100(1):138-43. doi: 10.1111/j.1349-7006.2008.01014.x. Epub 2008 Nov 24. Cancer Sci. 2009. PMID: 19037994 Free PMC article.

9

Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor.

Kamiryo Y, Eto M, Yamada H, Yajima T, Harano M, Takeuchi A, Tatsugami K, Hamaguchi M, Naito S, Yoshikai Y. Kamiryo Y, et al. Among authors: eto m. Cancer Res. 2009 Jun 15;69(12):5151-8. doi: 10.1158/0008-5472.CAN-08-2517. Epub 2009 Jun 2. Cancer Res. 2009. PMID: 19491277

10

Oral administration of xanthan gum enhances antitumor activity through Toll-like receptor 4.

Takeuchi A, Kamiryou Y, Yamada H, Eto M, Shibata K, Haruna K, Naito S, Yoshikai Y. Takeuchi A, et al. Among authors: eto m. Int Immunopharmacol. 2009 Dec;9(13-14):1562-7. doi: 10.1016/j.intimp.2009.09.012. Epub 2009 Sep 27. Int Immunopharmacol. 2009. PMID: 19788935

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,008 results

Search Page

Filters